|
SG2013013339A
(en)
*
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
CA2532067C
(en)
|
2003-07-24 |
2010-12-21 |
Stephen Douglas Barrett |
N-methyle-substituted benzamidazoles
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
KR101127201B1
(ko)
|
2003-09-22 |
2012-04-12 |
에스*바이오 피티이 리미티드 |
벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
KR101190912B1
(ko)
|
2003-11-19 |
2012-10-12 |
어레이 바이오파마 인크. |
Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
|
|
US7517994B2
(en)
*
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
AU2004293026B2
(en)
*
|
2003-11-21 |
2012-01-19 |
Array Biopharma Inc. |
AKT protein kinase inhibitors
|
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
ES2444866T3
(es)
|
2004-10-20 |
2014-02-27 |
Merck Serono Sa |
Derivados de 3-arilamino piridina
|
|
ES2330872T3
(es)
*
|
2004-12-01 |
2009-12-16 |
Merck Serono Sa |
Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
|
|
TWI441637B
(zh)
|
2005-05-18 |
2014-06-21 |
Array Biopharma Inc |
Ｍｅｋ雜環抑制劑及其使用方法
|
|
EP1904481B1
(en)
|
2005-06-23 |
2016-02-17 |
Array Biopharma, Inc. |
Process for preparing benzimidazole compounds
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
NZ567140A
(en)
*
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
WO2007071951A1
(en)
*
|
2005-12-21 |
2007-06-28 |
Astrazeneca Ab |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
WO2008006039A1
(en)
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Dihydrothieno pyrimidines as akt protein kinase inhibitors
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
RU2481336C2
(ru)
|
2006-07-06 |
2013-05-10 |
Эррэй Биофарма Инк. |
Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
|
|
DE602007011628D1
(de)
|
2006-07-06 |
2011-02-10 |
Array Biopharma Inc |
Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
|
|
ZA200901009B
(en)
*
|
2006-08-21 |
2010-05-26 |
Genentech Inc |
Aza-benzothiophenyl compounds and methods of use
|
|
CA2660546A1
(en)
*
|
2006-08-21 |
2008-02-28 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
|
WO2008024724A1
(en)
|
2006-08-21 |
2008-02-28 |
Genentech, Inc. |
Aza-benzothiophenyl compounds and methods of use
|
|
WO2008076415A1
(en)
|
2006-12-14 |
2008-06-26 |
Exelixis, Inc. |
Methods of using mek inhibitors
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
EP2164850B1
(en)
|
2007-06-12 |
2016-01-13 |
Genentech, Inc. |
N-substituted azaindoles and methods of use
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
MX2009014013A
(es)
|
2007-07-05 |
2010-01-28 |
Array Biopharma Inc |
Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
CA2692502C
(en)
|
2007-07-05 |
2016-03-01 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
US8022057B2
(en)
|
2007-11-12 |
2011-09-20 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
TWI441820B
(zh)
|
2007-12-19 |
2014-06-21 |
Genentech Inc |
５－苯胺咪唑并吡啶及使用方法
|
|
EP2231662B1
(en)
|
2007-12-19 |
2011-06-22 |
Genentech, Inc. |
8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
|
|
CA2708176A1
(en)
*
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
|
US8853216B2
(en)
*
|
2008-01-09 |
2014-10-07 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
|
|
US8835434B2
(en)
|
2008-01-09 |
2014-09-16 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
CA2727250A1
(en)
|
2008-07-01 |
2010-01-07 |
Genentech, Inc. |
Bicyclic heterocycles as mek kinase inhibitors
|
|
JP5615274B2
(ja)
|
2008-07-01 |
2014-10-29 |
ジェネンテック， インコーポレイテッド |
Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
|
|
AU2009279940B2
(en)
|
2008-08-04 |
2014-01-16 |
Merck Patent Gmbh |
Novel phenylamino isonicotinamide compounds
|
|
EP2346818B1
(en)
|
2008-11-10 |
2012-12-05 |
Bayer Intellectual Property GmbH |
Substituted sulphonamido phenoxybenzamides
|
|
EP2370568B1
(en)
|
2008-12-10 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
CN102574782B
(zh)
|
2009-10-21 |
2014-10-08 |
拜耳知识产权有限责任公司 |
取代的卤代苯氧基苯甲酰胺衍生物
|
|
CA2777430A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
US8962606B2
(en)
|
2009-10-21 |
2015-02-24 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
CA2789696C
(en)
|
2010-02-25 |
2017-11-07 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
EP2545187B1
(en)
|
2010-03-09 |
2018-09-05 |
Dana-Farber Cancer Institute, Inc. |
Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
|
|
KR101594002B1
(ko)
|
2010-10-06 |
2016-02-15 |
글락소스미스클라인 엘엘씨 |
Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
|
|
WO2012055953A1
(en)
|
2010-10-29 |
2012-05-03 |
Bayer Pharma Aktiengesellschaft |
Substituted phenoxypyridines
|
|
FI2694072T4
(fi)
|
2011-04-01 |
2024-09-30 |
Genentech Inc |
Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
|
|
TR201815685T4
(tr)
|
2011-04-01 |
2018-11-21 |
Genentech Inc |
Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
|
|
EP2714037B1
(en)
|
2011-05-25 |
2016-07-13 |
Université Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
CN103204825B
(zh)
|
2012-01-17 |
2015-03-04 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
|
|
WO2013169858A1
(en)
|
2012-05-08 |
2013-11-14 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
EP2854779A1
(en)
|
2012-05-31 |
2015-04-08 |
Bayer Pharma Aktiengesellschaft |
Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
|
|
SI2909188T1
(en)
|
2012-10-12 |
2018-07-31 |
Exelixis, Inc. |
A novel process for the manufacture of compounds for use in the treatment of cancer
|
|
US9913844B2
(en)
|
2013-03-21 |
2018-03-13 |
Novartis Ag |
Combination therapy
|
|
WO2015038704A1
(en)
|
2013-09-11 |
2015-03-19 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
|
CN109438362B
(zh)
*
|
2017-11-14 |
2020-07-21 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的苯并咪唑化合物及包含该化合物的组合物
|
|
CA3129665A1
(en)
|
2019-03-21 |
2020-09-24 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
KR20220098759A
(ko)
|
2019-11-08 |
2022-07-12 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키나제 억제제에 대해 내성을 획득한 암의 치료 방법
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
JP2024521788A
(ja)
|
2021-05-27 |
2024-06-04 |
ミラティ セラピューティクス， インコーポレイテッド |
併用療法
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
CN118973580A
(zh)
|
2022-04-08 |
2024-11-15 |
米拉蒂治疗股份有限公司 |
包含sos1抑制剂和mek抑制剂的组合疗法
|
|
EP4788839A1
(en)
|
2023-10-03 |
2026-08-12 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|